The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Bruno Jactel,in thr Proactive podcast stated that very large producers had "adopted our technology" and that they had "used our product to treat 100s of millions of chickens". Even if the product cost just one cent to treat ten chickens,surely the interim figures would have more reflected this level of uptake. Could anyone(ivyspivey,your field ?)provide an answer as to why revenues do not seem to be impacted by what is claimed by our CEO to be massive usage of PureScience products. To be fair,the Interims did announce that post period end saw the ," Launch of a new PureScience™ product for the poultry and swine markets in the US." It all looks pretty exciting to me and with each and every product said to be performing above expectations,we could well see a surprise on the upside,come the finals,never mind any benefits accruing from the strategic review.
Thanks for all the the informative opinions and articles put forward in the last few days it all adds up to a very strong future for tyratech. As I have said before I think the clean food side of Tyratechs technology will be the driving force in the next few years. You can not ignore a product that is pesticide free and has organic status and WORKS.
http://www.argylejournal.com/chief-marketing-officer/lily-robertson-from-argyle-executive-forum-interviewed-bruno-jactel-former-chief-marketing-officer-at-merial-limited-regarding-marketing-strategies-and-trends-in-the-animal-health-market/ I know this a few years old but at time BJ was at Merial and had a Senior Position. Thus nay help give an insight into one of the readons why I think they see the future in AH and they initiated Vamoose but was to raise money to develop the AH potential but now they will,achieve thus by divesting the Human side. Only my thoughts
and totally agree about ridiculously low valuation. But a great buying opportunity for those of us in the know, eh?
Historically the gap between the prices hasn't been that great, say over 5 years, but I take your point about liquidity. I think for most PIs it's too complicated and they just don't want to be bothered with filling in US tax forms. So why bother with TYRU then?
When "shareholder value" is delivered lospeculatore,it will accrue equally to both lines of stock. One obtains more shares via the TYR classification. Interestingly,the TYR line is currently far more liquid,albeit on a 38% spread,with MMs happy to deal in 500k blocks within the quote.. The gap between TYR and TYRU is not so pronounced at present.A few months ago it was possible to switch holdings and effect a net increase of 33% in total shares held. Each to his own though,for I am not advocating buying one against the other. I can well see the SP continuing to climb,on a managed basis,with my initial target being a recovery in the TYRU line to 2 pence, which even at that level only accords a derisory valuation to the company when one considers the topicality and growing recognition of the TyraTech IP.
A topic that keeps coming up on this and TYR board is what is the difference between the two. Why buy TYR? I'm 100% in TYRU so that I can trade it easily on a sudden rise in sp, if I want to.
I'd go along with Ivy here. We don't know what Pure Science is going to deliver in terms of sales yet, but all the referrals to animal health are very positive and it is a potentially much more lucrative market. Otherwise why sell rights to household pests to Envance and specifically retain rights for personal care and animal health (July RNS)?
Yes I suspect a US buyer and could well be a biopharma so valuations tend to be quite high. Think the advance deal as well as raising money is clearing the decks of non core stuff and also would be seen as attractive endorsement of any potential buyer
Thanks for those thoughts ivyspivey. If the human heath division is available for disposal then I wonder what valuation it might attract. Potentially more than the current market cap I would suspect.
You could be right and I have long thought the review would lead to a hive off the human side to concentrate on AH due to the background of the BOD. A couple of things which BJ said in the I/v just convinced me a bit more. The using of the money to concentrate on the US Vamoose sales when the marke has recovered to be the best possible valuation when I think they would have spent more in UK if they tended to keep Vamoose. The specific mention of the AH pipeline and the specific references to chicken mite and the reference to main US poultry Company's doing trials and knowing the oligopolistic nature of the industry means you can really build that side with a small team and a few strategic alliances. The mention of the industry and consumer sentiment was a big driver and BJs previous experience would put him in a great position to exploit this to the full. Only my thoughts as usual
Bruno Jactel,in his presentation today,went far beyond the detail contained in the interim accounts. I found it particularly interesting that the global consumer company had carried out due diligence over a two year period before entering into the agreement which was the subject of a RNS on July 4th. Could it be that similar due diligence is underway in respect of TyraTech as a whole, rather than just the human health side as put forward by ivyspivey ? Whatever transpires,the future looks bright for those invested here.I already hold significant amounts of TYRU and TYR shares and intend to add again tomorrow as long as the price remains subdued.
Just listened.very interesting and totally convinced now that the strategic direction will lead to Vamoose side being sold before end of the year and TYRU will focus solely on animal health. Cash for 12 months.Looks very good here imo
Just listened.very interesting and totally convinced now that the strategic direction will lead to Vamoose side being sold before end of the year and TYRU will focus solely on animal health. Cash for 12 months.Looks very good here imo
Thanks for that. Sounds encouraging. Let's hope for some very good news before the end of the year. As always with this share patience is the key.
Interim results out seem decent and should be good rest of 2017
There was a bit of a spike when the news came out but it did not last long. It appears to me that Tyru has some good products and great potential. However, sales of guardian in the USA and France will not affect the September update, neither will the sale of the outsmart fly spray. Hopefully a positive update on contracts in the poultry business.
http://www.lse.co.uk/share-regulatory-news.asp?shareprice=TYR&ArticleCode=701h9499&ArticleHeadline=Joint_Development_and_License_Agreement Envance ( joint venture between American Vanguard Corporation (NYSE: AVD) (AMVAC) which holds a 86.67% interest and TyraTech which holds 13.33%. AMVAC is also a 15.15% shareholder in TyraTech) has entered a Joint Development and License Agreement with a major global consumer products company (the "Corporation) to develop and commercialize a range of pest control household products based on TyraTech's nature-derived technologies. The Agreement which sub-licenses Envance's existing rights to TyraTech's intellectual property ("IP") and knowhow with applications in the consumer household pest control sector to the Corporation. The Agreement specifically excludes personal care products, which are the sole property of TyraTech, such as the Vamousse® range of head lice treatments; Guardian™ personal insect repellants; as well as Animal Health applications will,according to CEO Bruno Jactel,benefit Tyratech in at least three separate ways. Firstly all parties will share technology and expertise in the development of new products for use in controlling pests in the home environment, and new intellectual property created will be jointly owned. Significantly, TyraTech will gain the right to use the new IP in its own fields (personal care and animal health). Secondly,TyraTech will be entitled to a small share of the profit of Envance, derived from the royalties on the Corporation's net sales of these products. Separately, in recognition of the addition of further IP in the same household sector, Envance will pay TyraTech associated royalties and an additional upfront cash fee of $500,000 which will be used to fund normal working capital. Thirdly, it is envisaged that TyraTech will also be involved in the development of the new products in the first few years of the Agreement, which is being fully funded by Envance. TyraTech will receive a fee in relation to research and development services in line with the terms of its existing agreement with Envance." The Agreement sub-licenses Envance's existing rights to TyraTech's intellectual property ("IP") and knowhow with applications in the consumer household pest control sector to the Corporation. The Agreement specifically excludes personal care products, which are the sole property of TyraTech, such as the Vamousse® range of head lice treatments; Guardian™ personal insect repellants; as well as Animal Health applications. These benefits should serve to reduce TYRU R&D costs whilst broadening and strengthening its IP and serve to promote future profitability. These benefits seem to have passed under the market's/investors radar imo.
Some good research there, Luke. Thanks for that. I can wait till 2018. Tyratech have some impressive patents. Trouble is, most investors on AIM can't wait 2 days for a profit. Still loading up at this ridiculous price.
Dec 16th 2016 TyraTech, Inc. using EPIC/TICKER code LON:TYR had its stock rating noted as ‘Retains’ with the recommendation being set at ‘BUY’ this morning by analysts at Whitman Howard. TyraTech, Inc. are listed in the Basic Materials sector within AIM. Whitman Howard have set a target price of 9 GBX on its stock. This would imply the analyst believes there is now a potential upside of 452.1% from today’s opening price of 1.63 GBX. Over the last 30 and 90 trading days the company share price has decreased 0.19 points and decreased 0.36 points respectively.
http://www.proactiveinvestors.com/companies/news/123744/tyratech-inc-has-sizeable-opportunity-in-animal-health-market-says-whitman-123744.html This is joint broker Whitman Howard's 2016 note. I will post the 2017 detail once I gain access .
http://allenbycapital.com/research/research-tyratech_22_352808282.pdf An email provision secures the note. Estimated losses of US$ 1million for 2017 with break even forecast in 2018.
Not sure guess they mean an average head lice season but will look at numbers. What may be more interesting is to look at cash position and any mention of July/Aug sales of Vamoose and strategic review. Bruno normally a company's these results with I/vs